Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13
Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
